Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 508

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Prognostic and predictive value of PDL1 expression in breast cancer

Open access
Sabatier, Renaud, Finetti, Pascal, Mamessier, Emilie, Adelaide, José, Chaffanet, Max, Ali, Hamid Raza, Viens, Patrice, Caldas, Carlos, Birnbaum, Daniel, Bertucci, François·2015·Oncotarget
DOI 10.18632/oncotarget.3216
Open this paper in CoChat — free account

Abstract

// Renaud Sabatier 1,2,3 , Pascal Finetti 1 , Emilie Mamessier 1 , José Adelaide 1 , Max Chaffanet 1 , Hamid Raza Ali 4,5 , Patrice Viens 1,2,3 , Carlos Caldas 5 , Daniel Birnbaum 1 and François Bertucci 1,2,3 1 Département d’Oncologie Moléculaire, “Equipe labellisée Ligue Contre le Cancer”, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France 2 Département d’Oncologie Médicale, CRCM, Institut Paoli-Calmettes, Marseille, France 3 Faculté de Médecine, Aix-Marseille Université, Marseille, France 4 Department of Pathology, University of Cambridge, Cambridge, United Kingdom 5 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom Correspondence: François Bertucci, email: // Keywords : breast cancer, chemotherapy, immune response, PDL1, survival Received : November 17, 2014 Accepted : December 26, 2014 Published : December 31, 2014 Abstract Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different carcinomas with correlation between PDL1 tumor expression and responses. We retrospectively analyzed PDL1 mRNA expression in 45 breast cancer cell lines and 5,454 breast cancers profiled using DNA microarrays. Compared to normal breast samples, PDL1 expression was upregulated in 20% of clinical samples and 38% of basal tumors. High expression was associated with poor-prognosis features (large tumor size, high grade, ER-negative, PR-negative, ERBB2- positive status, high proliferation, basal and ERBB2 -enriched subtypes). PDL1 upregulation was associated with biological signs of strong cytotoxic local immune response. PDL1 upregulation was not associated with survival in the whole population, but was associated with better metastasis-free and overall specific survivals in basal tumors, independently of clinicopathological features. Pathological complete response after neoadjuvant chemotherapy was higher in case of PDL1 upregulation (50% versus 21%). In conclusion, PDL1 upregulation, more frequent in basal breast cancers, was associated with increased T-cell cytotoxic immune response. In this aggressive subtype, upregulation was associated with better survival and response to chemotherapy. Reactivation of dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent promising strategy in PDL1-upregulated basal breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3216

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 508

Metadata

Authors
Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F.
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2014-12-31
Volume
6
Issue
7
Pages
5449-5464
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.3216
OpenAlex
W2143459396
Cited by
508
References
76
FWCI
17.95
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.